Compare Revvity Inc (RVTY) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Visa Inc — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while Visa Inc trades at $359.71 (market cap $671.74B). The key difference: Visa Inc is far larger — about 52× Revvity Inc's market cap, and Visa Inc pays the higher dividend (0.74%). Which is the better fit depends on your goals.
| RVTY | V | |
|---|---|---|
Market Cap | $12.91B | $671.74B |
Sector | Technology | Financials |
52-Week High | $117.75 | $370.47 |
52-Week Low | $82.26 | $295.52 |
Enterprise Value | $15.23B | $682.32B |
Dividend Yield | 0.24% | 0.74% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Visa (V) trades at $360.00, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.32, and maintains robust fundamentals including a 50.78% net income margin and $20.06B net income for 2025. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for growth in digital payments.
The outlook for Visa remains positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 18% upside. Key risks include competitive pressures from fintech and regulatory scrutiny, but sustained revenue growth and high profitability support long-term investor appeal. The stock's valuation at a P/E of 30.88 reflects premium pricing justified by its market leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
